NXTC · NextCure, Inc.
$7.68
-0.14 (-1.79%)
At close · Sep 8
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these unaudited financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$35.79M
Shares
4.58M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$22.38M
+252.6%
FY2020
Net Income
-$55.84M
-0.3%
FY2025
Operating Margin
-184.22%
+406.3pp
FY2020
Diluted EPS
-$19.65
+17.7%
FY2025
Operating Cash Flow
-$49.61M
-21.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $22.38M | $6.35M | — | |
| $27.2M | $44.92M | $41.49M | $47.93M | $54.2M | $50.19M | $46.55M | $34.22M | $19.79M | |
| $11.63M | $12.69M | $15.72M | $19.71M | $21.71M | $20.57M | $17.05M | $9.61M | $3.41M | |
| — | $2.2M | $2.9M | $3.7M | $4.1M | $4.3M | $3.4M | $2.69M | $1.68M | |
| $43.9M | $57.62M | $59.75M | $67.64M | $75.91M | $70.77M | $63.6M | $43.83M | $23.2M | |
| -$43.9M | -$57.62M | -$59.75M | -$67.64M | -$75.91M | -$70.77M | -$41.23M | -$37.48M | -$23.2M | |
| — | — | — | — | — | — | -184.22% | -590.55% | — | |
| — | -$55.42M | -$56.85M | -$63.94M | -$71.81M | -$66.47M | -$37.83M | -$34.79M | -$21.52M | |
| — | — | — | — | — | — | $183K | $209K | $25K | |
| $1.15M | $1.77M | $4.09M | $4.91M | $1.18M | $1.38M | $4.62M | $3.75M | $397K | |
| $0 | $0 | — | — | — | — | — | — | — | |
| -$42.75M | -$55.84M | -$55.65M | -$62.72M | -$74.73M | -$69.39M | -$36.6M | -$33.74M | -$22.8M | |
| — | — | — | — | — | — | -163.57% | -531.54% | — | |
| -$42.74M | -$55.83M | -$55.43M | -$61.45M | -$75.56M | -$70.83M | -$35.82M | -$33.78M | -$22.8M | |
| USD/shares | -$8.33 | -$19.65 | -$23.88 | -$27.00 | -$32.28 | -$30.12 | -$15.96 | — | — |
| USD/shares | -$8.33 | -$19.65 | -$23.88 | -$27.00 | -$32.28 | -$30.12 | -$15.96 | — | — |
| shares | — | 2.84M | 2.33M | 2.32M | 2.31M | 2.3M | 2.29M | 1.31M | 114.15K |
| shares | — | 2.84M | 2.33M | 2.32M | 2.31M | 2.3M | 2.29M | 1.31M | 114.15K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.62×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.94×
Peer medians compare against the 268 similar-size Biotechnology companies (of 537 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1661059
CUSIP
65343E207
13F (30d)
27 filings
27 filers
Visit website
Investor relations